Navigation Links
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
Date:5/16/2012

PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy.

"These results add to the evidence that the combination of standard therapies such as stem cell transplantation with the emerging biologic therapies, like lenalidomide, have extended the lives of multiple myeloma patients," said Richard Maziarz, M.D., of the OHSU Knight Cancer Institute who was one of the study's co-authors. Maziarz serves as medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the OHSU Knight Cancer Institute. "We know that for at least three years following a transplant that maintenance therapy with this drug vastly improves the chances that the cancer won't come back and worsen."

These data were supported by similar Phase III studies reported from France and Italy in the same issue of the New England Jounal of Medicine demonstrating that maintenance therapy after stem cell transplantation was associated with improved disease control.

Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell normally responsible for producing antibodies. In patients impacted by multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, interfering with the production of normal blood cells. The study focused on patients who received an autologous hematopoietic cell transplant (AHCT). AHCT procedures use patients' own blood stem cells.

While lenalidomide increased a patient's ability to stave off progression of the disease, questions remain regarding future approaches recognizing that quality of life measurements were not incorporated within these studies, that long-term safety issues remain unclear as there was a small but discernable risk of second cancers observed in the treated patients. In addition to the need for that cost-benefit analysis, a comparison remains to be performed with other emerging myeloma maintenance therapies.

This Phase III study of lenalidomide was conducted at 47 medical centers and involved 568 patients. It was sponsored by the National Cancer Institute (NCI). Revlimid's manufacturer, Celgene Corp., provided the NCI with lenalidomide for this research.


'/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-4530
Oregon Health & Science University
Source:Eurekalert  

Related medicine news :

1. Study urges caution with lenalidomide dosage
2. How to recognize at an early stage whether a new cancer therapy prolongs life
3. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
4. Early life stress may predict cardiovascular disease
5. Study finds racial gaps continue in heart disease awareness
6. Bowel disease link to blood clots
7. Womens Heart Disease Awareness Still Lacking
8. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
9. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
(Date:5/21/2020)... ... May 21, 2020 , ... Casenet® LLC today released ... supports care management and utilization management at health insurance plans. Developed over two ... provides significant usability and automation upgrades to all of its existing features, introduces ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... JNL ... care industry announced the release of the SafeHealth screening software. This tool ... the need for additional staff or the cost of additional paperwork management. , SafeHealth ...
(Date:5/16/2020)... ... May 15, 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D ... has always had in place. After being allowed to re-open during the current pandemic, they ... staff are as safe and comfortable as possible while going through their dental exams and ...
(Date:5/16/2020)... ... May 15, 2020 , ... ... new collaboration with the Open Source Medical Supplies (OSMS). The organization will obtain ... efforts to reduce the spread of COVID-19. , Created as a response to ...
(Date:5/15/2020)... ... May 15, 2020 , ... COVID-19 has made people feel fearful, but Rieke ... their employees can get back to work safely. Their unique line of SafeSpace™ PPE ... bars, and countless other settings. , Everyone needs to be able to get back ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... ... May 29, 2020 , ... United ... to the U.S. announcement that it will terminate its relationship with the World ... it plans to terminate its relationship with the World Health Organization. Any move ...
(Date:5/30/2020)... ... May 30, 2020 , ... ... a host of new issues related to COVID-19. Recently, Wellness Expert Jamie Hess ... expectant moms support their pregnancy and postpartum. , A video accompanying this ...
(Date:5/28/2020)... ... May 28, 2020 , ... May is Talking is Power Month, a national ... care about them. The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted ... Power to Decide’s Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and ...
Breaking Medicine Technology: